Biocryst Pharmaceuticals Inc

NASDAQ: BCRX
$7.78
+$0.11 (+1.4%)
Closing Price on November 8, 2024

BCRX Stock Chart and Intraday Price

BCRX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,158.56M USD
Shares Outstanding 206,150,000
Biocryst Pharmaceuticals Inc is a biotechnology firm focused on developing treatments for rare diseases. It offers RAPIVAB, RAPIACTA, and PERAMIFLU, which are brands of peramivir injection for acute influenza, and ORLADEYO, an oral treatment for hereditary angioedema. The company is also working on BCX10013, targeting complement-mediated diseases. Founded in 1986 and based in Durham, North Carolina, Biocryst collaborates with various global institutions and companies to advance its research and development efforts.

BCRX Articles

These five candidates to be the best-performing growth stock over the next five years include biotech, energy, and software stocks.
Tuesday's top analyst upgrades and downgrades included Adobe, Annaly Capital Management, BioCryst Pharmaceuticals, Carvana, DoorDash, Kimco Realty, Micron Technology, Netflix, Nike, PayPal and Zim...
Monday's top analyst upgrades and downgrades included Amazon.com, Amgen, Apple, BioCryst Pharmaceuticals, Block, Coinbase Global, Datadog, Fortinet, Gilead Sciences, Intercontinental Exchange,...
Thursday's top analyst upgrades and downgrades included Alcoa, American International Group, BioCryst Pharmaceuticals, Coinbase Global, GitLab, Home Depot, Merck, Nvidia, Palo Alto Networks,...
Thursday's top analyst upgrades and downgrades included BioCryst Pharmaceutical, Canopy Growth, Cleveland-Cliffs, Datadog, Electronic Arts, Palo Alto Networks, Peloton Interactive, Snowflake, SoFi...
Friday's additional top analyst upgrades and downgrades included Acadia Pharmaceuticals, BioCryst Pharmaceuticals, Duke Energy, Kellogg, Paramount Global, Rhythm Pharmaceuticals and Teva...
Friday's top analyst upgrades and downgrades included AppLovin, BioCryst Pharmaceuticals, Boeing, CF Industries, Coupa Software, Crocs, Dutch Bros, DigitalOcean, Gilead Sciences, IBM, International...
Monday’s additional top analyst upgrades and downgrades included Aptiv, BioCryst Pharmaceuticals, CSX, Gap, Nektar Therapeutics, Progressive, Peloton Interactive, Sirius XM and United Airlines.
Monday's top analyst upgrades and downgrades included Alibaba, AT&T, Baidu, Bilbili, CommScope, JetBlue Airways, Navient, Nvidia, Pinduoduo, Schlumberger, Sea, State Street, Truist Financial, U.S....
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Tuesday, including Affirm, BioCryst Pharmaceuticals, Exxon Mobile, First Solar and Tesla.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including BioCryst, Editas, Groupon, Sunrun, Twitter and more.
Ford, General Electric and these other stocks are likely to survive the current troubles and could very well offer patient investors some huge returns over the next year or so.
Tuesday's top analyst upgrades and downgrades included AppFolio, BioCryst Pharmaceuticals, Booking, DraftKings, Intuit, L Brands, Peloton Interactive, Salesforce.com and Wells Fargo.
As with almost all pandemic scares and other national and global issues, some speculative stocks manage to see their shares rise sharply.
The Wuhan Coronavirus has escaped China, with the number of cases and the death toll rising. The economic impact beyond the loss of life and suffering is real in many stocks, sectors and local...